Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.

Galanina N, Jasielec J, Peace D, Smith SM, Nabhan C.

Leuk Lymphoma. 2016 Jul 14:1-2. [Epub ahead of print] No abstract available.

PMID:
27415580
2.

Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma.

Nabhan C, Smith SM, Cifu AS.

JAMA. 2016 May 17;315(19):2115-6. doi: 10.1001/jama.2016.4913. No abstract available.

PMID:
27187305
3.

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.

Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR.

Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401. Epub 2016 May 24.

PMID:
27124800
4.

Use of class I histone deacetylase inhibitor romidepsin in combination regimens.

Petrich A, Nabhan C.

Leuk Lymphoma. 2016 Aug;57(8):1755-65. doi: 10.3109/10428194.2016.1160082. Epub 2016 Apr 27.

PMID:
27118119
5.

Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.

Nabhan C, Chaffee KG, Slager SL, Galanina N, Achenbach SJ, Schwager SM, Kay NE, Shanafelt TD.

Am J Hematol. 2016 Jul;91(7):677-80. doi: 10.1002/ajh.24374. Epub 2016 Apr 24.

PMID:
27013143
6.

The evolving role of lenalidomide in non-Hodgkin lymphoma.

Galanina N, Petrich A, Nabhan C.

Leuk Lymphoma. 2016 Jul;57(7):1507-16. doi: 10.3109/10428194.2016.1146949. Epub 2016 Feb 22.

PMID:
26902680
7.

Oncology Pathways-Preventing a Good Idea From Going Bad.

Polite BN, Page RD, Nabhan C.

JAMA Oncol. 2016 Mar;2(3):297-8. doi: 10.1001/jamaoncol.2015.5778. No abstract available.

PMID:
26847876
8.

Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.

Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD.

Haematologica. 2016 Apr;101(4):458-65. doi: 10.3324/haematol.2015.136556. Epub 2016 Jan 27.

9.

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.

Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL.

Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727.

10.

Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.

Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ.

Blood. 2016 Feb 25;127(8):1064-7. doi: 10.1182/blood-2015-12-686873. Epub 2015 Dec 23. No abstract available.

PMID:
26702066
11.

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C.

Cancer. 2016 Feb 15;122(4):559-64. doi: 10.1002/cncr.29781. Epub 2015 Nov 13.

PMID:
26565895
12.

The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.

Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M.

Curr Hematol Malig Rep. 2015 Dec;10(4):448-55. doi: 10.1007/s11899-015-0291-0.

PMID:
26449717
13.

Prognosis in Chronic Lymphocytic Leukemia-Reply.

Nabhan C, Raca G, Wang YL.

JAMA Oncol. 2015 Oct;1(7):988-9. doi: 10.1001/jamaoncol.2015.2532. No abstract available.

PMID:
26448290
14.

Prostate Cancer Screening.

Eggener SE, Cifu AS, Nabhan C.

JAMA. 2015 Aug 25;314(8):825-6. doi: 10.1001/jama.2015.8033. No abstract available.

PMID:
26305653
15.

The Future of Cancer Care: Are We Ready For Personalized Value?

de Souza JA, Kelly C, Nabhan C.

J Natl Compr Canc Netw. 2015 Aug;13(8):1049-51. No abstract available.

PMID:
26285249
16.

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.

Nabhan C, Raca G, Wang YL.

JAMA Oncol. 2015 Oct;1(7):965-74. doi: 10.1001/jamaoncol.2015.0779. Review.

PMID:
26181643
17.

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.

Am J Hematol. 2015 Sep;90(9):778-83. doi: 10.1002/ajh.24082.

PMID:
26044261
18.

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.

George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG.

Cancer Immunol Res. 2015 Sep;3(9):1063-9. doi: 10.1158/2326-6066.CIR-15-0006. Epub 2015 May 5.

PMID:
25943532
19.

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.

Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR.

Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399. Epub 2015 Apr 7.

PMID:
25851937
20.

Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.

Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA.

J Geriatr Oncol. 2015 May;6(3):211-8. doi: 10.1016/j.jgo.2015.01.003. Epub 2015 Jan 19.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk